<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689598</url>
  </required_header>
  <id_info>
    <org_study_id>C07061</org_study_id>
    <nct_id>NCT00689598</nct_id>
  </id_info>
  <brief_title>Spironolactone for Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>Use of Spironolactone to Treat Patients With Paroxysmal Atrial Fibrillation- A Multi-Center, Prospective, Randomized, Placebo-Controlled, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether or not spironolactone can prevent or delay the occurrence of atrial
      fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether or not adding spironolactone can prevent or delay the occurrence of
      paroxysmal atrial fibrillation in patients who have received propafenone treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to a first electrocardiographically confirmed AF</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Response rate: Improvement of any symptom scores and/or SF36 scores more than 50 % (compared with re-randomization scores) 2. Difference of mean episodes of documented AF between the spironolactone and placebo groups.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>25 mg po qd 25 mg po bid</description>
    <arm_group_label>III</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Spironolactone 25 mg po qd</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. 18 to 80 Y/O,

          2. Paroxysmal AF.

        Exclusion criteria:

          1. GPT&gt;100 IU/L or tota bilirubin &gt;2 mg/dl;

          2. Creatinine &gt; 2 mg/dl;

          3. Serum potassium &gt;= 5 mM;

          4. Serum sodium &lt;=130 mM;

          5. Uric acid &gt; 10 mg/dlã€‚
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsu-Juey Wu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>TCVGH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tsu-Juey Wu, M.D.</last_name>
    <phone>886-4-23592525</phone>
    <phone_ext>4043</phone_ext>
    <email>tjwu@vghtc.vghtc.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taichung General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsu-Juey Wu, M.D.</last_name>
      <phone>886-4-23592525</phone>
      <phone_ext>4043</phone_ext>
      <email>tjwu@vghtc.vghtc.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>June 4, 2008</last_update_submitted>
  <last_update_submitted_qc>June 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tsu-Juey Wu, M.D./Staff Physician</name_title>
    <organization>Taichung Veterans General Hospital</organization>
  </responsible_party>
  <keyword>Atrial fibrillation, spironolactone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

